New Drug Product: Nubeqa
This slideshow reviews drug information for Nubeqa. Click here for the complete Nubeqa monograph.
Prostate And Other Male Cancers
Supplemental NDA for Xtandi Accepted and Granted Priority Review
The FDA has accepted a supplemental New Drug Application for Xtandi (enzalutamide; Astellas Pharma), that aims to expand the treatment indication to men with metastatic hormone-sensitive prostate cancer.
FDA: Entacapone Not Associated With Increased Prostate Cancer Risk
The FDA has concluded that the use of entacapone to treat Parkinson disease (PD) does not increase the risk of developing prostate cancer.
FDA Approves Prostate Cancer Treatment Nubeqa
The FDA has approved Nubeqa (darolutamide; Bayer), an androgen receptor inhibitor, for the treatment of patients with nonmetastatic castration resistant prostate cancer (nmCRPC).
Sugary Beverage Consumption Linked to Increased Cancer Risk
In prospective cohort study, consuming 100 percent fruit juice also tied to increased cancer risk
WHO Updates List of Essential Medicines
The World Health Organization (WHO) has updated the WHO Model List of Essential Medicines for 2019.
Androgen Deprivation Therapy May Up Risk of Alzheimer Disease
ADT exposure linked to subsequent Alzheimer disease diagnosis among elderly men at eight years
Testicular Cancer Treatment Does Not Up Risk for Offspring Birth Defects
No increased risk seen at posttreatment in children of fathers with testicular germ-cell cancer.
Zytiga Prescribing Information Updated With New Warnings
The prescribing information for Zytiga (abiraterone acetate; Janssen Biotech) has been updated to include new warnings and clinical data.
Prostate Cancer Diagnosis Risk Lower in Users of Hydrophilic Statins
Users of hydrophilic, but not hydrophobic, statins, had a lower risk of being diagnosed with prostate cancer, a large retrospective study found.
